Chong, Chloe
Müller, Markus http://orcid.org/0000-0003-0907-3583
Pak, HuiSong
Harnett, Dermot
Huber, Florian
Grun, Delphine
Leleu, Marion
Auger, Aymeric
Arnaud, Marion
Stevenson, Brian J.
Michaux, Justine
Bilic, Ilija http://orcid.org/0000-0002-2730-1634
Hirsekorn, Antje
Calviello, Lorenzo
Simó-Riudalbas, Laia
Planet, Evarist
Lubiński, Jan
Bryśkiewicz, Marta
Wiznerowicz, Maciej http://orcid.org/0000-0003-4960-6321
Xenarios, Ioannis
Zhang, Lin http://orcid.org/0000-0003-1998-0611
Trono, Didier
Harari, Alexandre http://orcid.org/0000-0002-1055-2090
Ohler, Uwe http://orcid.org/0000-0002-0881-3116
Coukos, George http://orcid.org/0000-0001-8813-7367
Bassani-Sternberg, Michal http://orcid.org/0000-0002-1934-954X
Funding for this research was provided by:
The German Federal Ministry of Education and Research
The Ludwig Institute for Cancer Research and the ISREC Foundation thanks to a donation from the Biltema Foundation
Article History
Received: 17 June 2019
Accepted: 12 February 2020
First Online: 10 March 2020
Competing interests
: G.C. has received grants and research support from BMS, Celgene, Boehringer Ingelheim, Roche, Lovance and Kite, and worked with them as a coinvestigator in clinical trials. G.C. has received honouraria for consultations or presentations from Roche, Genentech, BMS, AstraZeneca, Sanofi-Aventis, Nextcure, and GeneosTx. G.C. has patents regarding antibodies and vaccines targeting the tumor vasculature as well as technologies related to T cell expansion and engineering for T cell therapy. G.C. receives royalties from the University of Pennsylvania. The remaining authors declare no competing interests.